Incyte Corp. (INCY): Price and Financial Metrics
INCY Price/Volume Stats
| Current price | $58.10 | 52-week high | $86.29 |
| Prev. close | $58.81 | 52-week low | $57.91 |
| Day low | $57.91 | Volume | 2,306,800 |
| Day high | $59.34 | Avg. volume | 1,767,047 |
| 50-day MA | $63.57 | Dividend yield | N/A |
| 200-day MA | $70.71 | Market Cap | 13.02B |
INCY Stock Price Chart Interactive Chart >
INCY POWR Grades
- Quality is the dimension where INCY ranks best; there it ranks ahead of 97.98% of US stocks.
- The strongest trend for INCY is in Value, which has been heading up over the past 179 days.
- INCY ranks lowest in Momentum; there it ranks in the 16th percentile.
INCY Stock Summary
- INCY has a market capitalization of $13,335,458,729 -- more than approximately 86.76% of US stocks.
- The ratio of debt to operating expenses for INCYTE CORP is higher than it is for about merely 5.32% of US stocks.
- Equity multiplier, or assets relative to shareholders' equity, comes in at 1.31 for INCYTE CORP; that's greater than it is for just 17.93% of US stocks.
- If you're looking for stocks that are quantitatively similar to INCYTE CORP, a group of peers worth examining would be ABEO, ADAP, LNTH, SABS, and PTN.
- Visit INCY's SEC page to see the company's official filings. To visit the company's web site, go to www.incyte.com.
INCY Valuation Summary
- In comparison to the median Healthcare stock, INCY's price/earnings ratio is 33.58% higher, now standing at 36.4.
- INCY's price/sales ratio has moved down 1.8 over the prior 243 months.
Below are key valuation metrics over time for INCY.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| INCY | 2023-09-18 | 3.8 | 2.8 | 36.4 | 18.2 |
| INCY | 2023-09-15 | 4.0 | 3.0 | 38.2 | 19.5 |
| INCY | 2023-09-14 | 4.0 | 3.0 | 38.8 | 19.8 |
| INCY | 2023-09-13 | 4.0 | 3.0 | 38.6 | 19.7 |
| INCY | 2023-09-12 | 4.1 | 3.0 | 39.3 | 20.1 |
| INCY | 2023-09-11 | 4.1 | 3.0 | 39.4 | 20.2 |
INCY Growth Metrics
- Its 3 year revenue growth rate is now at 55.94%.
- Its 2 year revenue growth rate is now at 39.71%.
- Its 3 year net income to common stockholders growth rate is now at 268.87%.
The table below shows INCY's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-12-31 | 3,394.635 | 969.941 | 340.66 |
| 2022-09-30 | 3,330.788 | 801.63 | 876.05 |
| 2022-06-30 | 3,320.472 | 760.347 | 945.014 |
| 2022-03-31 | 3,114.784 | 759.134 | 933.038 |
| 2021-12-31 | 2,986.267 | 749.488 | 948.581 |
| 2021-09-30 | 2,912.923 | 741.458 | 534.58 |
INCY's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- INCY has a Quality Grade of A, ranking ahead of 95.94% of graded US stocks.
- INCY's asset turnover comes in at 0.76 -- ranking 198th of 563 Business Services stocks.
- TSSI, APDN, and NUAN are the stocks whose asset turnover ratios are most correlated with INCY.
The table below shows INCY's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 0.760 | 0.951 | 0.546 |
| 2021-06-30 | 0.754 | 0.949 | 0.381 |
| 2021-03-31 | 0.787 | 0.951 | 0.523 |
| 2020-12-31 | 0.831 | 0.951 | -0.231 |
| 2020-09-30 | 0.774 | 0.948 | -0.298 |
| 2020-06-30 | 0.758 | 0.949 | -0.138 |
INCY Price Target
For more insight on analysts targets of INCY, see our INCY price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $102.47 | Average Broker Recommendation | 1.56 (Moderate Buy) |
Incyte Corp. (INCY) Company Bio
ncyte is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware, and Morges, Switzerland. The company was created in 2002 through the merger of Incyte Pharmaceuticals, founded in Palo Alto, California in 1991 and Incyte Genomics, Inc. of Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia. (Source:Wikipedia)
Latest INCY News From Around the Web
Below are the latest news stories about INCYTE CORP that investors may wish to consider to help them evaluate INCY as an investment opportunity.
3 Biotech Stocks That Should Be on Every Investor’s Radar This FallEven with higher for longer interest rates, drug discovery moves on. |
13 Best Beaten Down Stocks To Buy NowIn this article, we will be taking a look at the 13 best beaten down stocks to buy now. To skip our detailed analysis of the US stock market and recent developments within it, you can go directly to see the 5 Best Beaten Down Stocks To Buy Now. The Two-Day Fed Meeting On September […] |
Incyte Hits Five-Year Low After GSK Snags Approval For A New Jakafi RivalIncyte stock tumbled to a nearly five-year low Monday after GSK gained FDA approval for a rival myelofibrosis treatment. |
Unveiling Incyte (INCY)'s Value: Is It Really Priced Right? A Comprehensive GuideAn In-depth Analysis of Incyte (INCY)'s Intrinsic Value and Market Position |
FDA approves GSK's unique myelofibrosis treatment OjjaaraThe US Food and Drug Administration (FDA) has approved GlaxoSmithKline's (NYSE:GSK) novel treatment, Ojjaara (momelotinib), for adults with intermediate- or high-risk myelofibrosis and anemia. This announcement comes after a three-month delay due to the need for additional data review. |
INCY Price Returns
| 1-mo | -9.54% |
| 3-mo | -6.97% |
| 6-mo | -17.95% |
| 1-year | -13.14% |
| 3-year | -32.42% |
| 5-year | -12.61% |
| YTD | -27.66% |
| 2022 | 9.43% |
| 2021 | -15.61% |
| 2020 | -0.39% |
| 2019 | 37.32% |
| 2018 | -32.86% |
Continue Researching INCY
Want to do more research on Incyte Corp's stock and its price? Try the links below:Incyte Corp (INCY) Stock Price | Nasdaq
Incyte Corp (INCY) Stock Quote, History and News - Yahoo Finance
Incyte Corp (INCY) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...